Search

Author/Creator Rangachari, L.

1. 300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma. Issue 3 (September 2015)

Authors:
Rasco, D.W.; Middleton, M.R.; Gonzalez, R.; Corrie, P.; Pavlick, A.; Lorigan, P.; Plummer, R.; Gore, M.; Herbert, C.; Agarwala, S.S.; Logan, T.F.; Khleif, S.N.; Papadopoulos, K.P.; Rangachari, L.; Suri, A.; Xu, Q.; Kneissl, M.; Bozón, V.; Olszanski, A.J.
Journal:
European journal of cancer
Issue:
Volume 51:Issue 3(2015:Feb.)
Page Start:
S53
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Pharmacokinetics (PK) of alisertib (MLN8237) in adult patients (pts) with advanced solid tumors or relapsed/refractory lymphoma with varying degrees of hepatic function. (December 2016)

Authors:
Zhou, X.; Lockhart, A.C.; Fu, S.; Nemunaitis, J.; Sarantopoulos, J.; Smith, D.; Muehler, A.; Rangachari, L.; Bargfrede, M.; Huebner, D.; Venkatakrishnan, K.
Journal:
European journal of cancer
Issue:
Volume 69(2016)supplement 1
Page Start:
S115
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search